Proactive Investors - Run By Investors For Investors

The Edge CEO: Why Merck & Co should spin off its animal health division

The Edge Consulting Group CEO Jim Osman tells Proactive Investors the investment research company that focuses on company spin-offs has compiled a report suggesting Merck & Co (NYSE:MRK) spin-off its animal health business, as the animal health business generates around $40 billion in revenue, The Edge expecting this to rise to $65 billion in 2025.

Osman says there's significant value to be held to create even more value for its investors if the pharma giant does indeed spin off this portion of the business.

Meet Cornish Lithium, Salt Lake Potash Ltd and Concepta at our event, London , 05 June 2019. Register here »
View full MRK profile View Profile

Merck & Co Timeline

June 09 2014

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use